The first human trials of a designed-in-Canada Ebola vaccine suggest it is safe and triggers a rapid immune response, two articles published Wednesday reveal. The work, based on six clinical trials in the United States, Switzerland, Germany, Gabon and Kenya, found the vaccine quickly generates antibodies in people who receive it.

Click here to read original article